BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
nitric oxide metabolic process
,
Allergy to pollen
,
Hippocampus
,
Biofuel
,
Quercetin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
anergy
(phenotype)
Summary
General Info
Genetic Markers
Most Correlated Genes
Most Correlated SNPs
EYA2
CARD11
VSIG1
CD27
JCHAIN
No SNPs found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
QI_PLASMACYTOMA_UP
positive regulation of leukocyte cell-cell adhesion
HAY_BONE_MARROW_PLASMA_CELL
immune response
AIZARANI_LIVER_C8_RESIDENT_B_CELLS_1
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Basophils anergic or reactive stimulated with anti-FCER1A antibodies
B cells naive from B cell Expansion with NF-kappaB and T cell Anergy disease patients IL-2 stimulate
OMIM - B-cell expansion with NFKB and T-cell anergy
Explore Curated Studies Results
Literature
Most Relevant Literature
NFAT1 supports tumor-induced anergy of CD4(+) T cells.
Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy…
Tumor suppressor TSC1 is critical for T-cell anergy.
Molecular mechanisms of T-cell anergy.
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy
RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART)
Peptide Vaccinations Plus GM-CT-01 in Melanoma
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian …
Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ